~~<i id='CBCF5229BA'><strike id='CBCF5229BA'><tt id='CBCF5229BA'><pre id='CBCF5229BA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：Wikipedia 2025-10-01 11:02:23 - browse：327

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

leisure time

entertainment

focus

entertainment

focus

0:58LindsayLohanandBaderShammasattendaneventonNov.9,2022,inNewYork.BryanBedder/GettyImages,FILELinds

WSS

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

In 'major milestone,' FDA approves first cell therapy for solid tumors

Ukraine seeks to reclaim its role as a hub for clinical trials

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

entertainment

fashion

leisure time

Apple is now the first public company to be valued at $3 trillion

Researchers tackle phage therapy hurdles for wider adoption

Supreme Court strikes down use of affirmative action

As AI regulations shape up, health tech startups beg for clarity

Cancer drug shortages should be causing more outrage

New study raises questions about niacin and heart health

After affirmative action ruling, medical educators look to 'holistic review'

'Reaching a detente': STAT's Helen Branswell on covering Covid

Drug repurposing or repositioning? The language matters

Ebola public health emergency is over, WHO declares

entertainment

MD Anderson's Padmanee Sharma responds to research credit suit

Measles policy set amid Florida outbreak alarms vaccine proponents

FDA warns medical device makers about rise in fabricated data

Plane’s emergency slide plummets from sky, hits Chicago home

TikTok cracks down on users posting about weight loss drugs

Secretariat’s lessons for human medicine

focus

entertainment

focus

focus